Compile Data Set for Download or QSAR
Report error Found 140 Enz. Inhib. hit(s) with all data for entry = 4583
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404296(1-[2-({(2R,5R)-5-[3-(1-Hydroxy- 1-methylethyl)isox...)
Affinity DataIC50: 8.80nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404309(((1R)-2,2,2-Trifluoro-1-{5-[(3R,6R)-6-methyl-1-{[2...)
Affinity DataIC50: 11nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404327(2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-y...)
Affinity DataIC50: 13.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404326(((2R,5R)-5-[3-(1-Methoxy-1-methylethyl)isoxazol-5-...)
Affinity DataIC50: 14.4nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404279(US10017504, 12)
Affinity DataIC50: 15nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404274(US10017504, 10 | US10017504, 9)
Affinity DataIC50: 15.6nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404310(US10017504, 41)
Affinity DataIC50: 17.5nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404330(2-{3-[(3R,6R)-1-{[4-Fluoro-2-(2H-1,2,3- triazol-2-...)
Affinity DataIC50: 18.6nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404331(1-[2-({(2R,5R)-5-[5-(1-Hydroxy-1- methylethyl)isot...)
Affinity DataIC50: 19.1nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404335(2-{3-[(3R,6R)-6-Methyl-1-{[4-(2H-1,2,3- triazol-2-...)
Affinity DataIC50: 21.1nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404337(2-{3-[(3R,6R)-6-Methyl-1-{[2- (trifluoromethoxy)ph...)
Affinity DataIC50: 22.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404293(2-{5-[(3R,6R)-1-(Biphenyl-2- ylcarbonyl)-6-methylp...)
Affinity DataIC50: 22.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404283(US10017504, 16)
Affinity DataIC50: 24.3nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404340(US10017504, 17)
Affinity DataIC50: 24.5nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404328((2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-...)
Affinity DataIC50: 24.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404274(US10017504, 10 | US10017504, 9)
Affinity DataIC50: 25.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404313(1-(2-{[(2R,5R)-2-Methyl-5-{3-[(1R)- 2,2,2-Trifluor...)
Affinity DataIC50: 26.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404285(((2R,5R)-5-[5-(1-Methoxy-1-methylethyl)isoxazol-3-...)
Affinity DataIC50: 27.3nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404286((2-{5-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-...)
Affinity DataIC50: 30.3nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404282(US10017504, 15)
Affinity DataIC50: 33.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404322(1-cyclopropyl-1-{5-[(3R,6R)-6-methyl-1-{[2-(2H-1,2...)
Affinity DataIC50: 34.3nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404281(US10017504, 14)
Affinity DataIC50: 34.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404333((2-(3-{(3R,6R)-6-Methyl-1-[(2-pyrimidin-2-ylthioph...)
Affinity DataIC50: 36.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404323(US10017504, 55 | 2-{5-[(3R,6R)-6-Methyl-1- {[2-(2H...)
Affinity DataIC50: 39.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404314(1-(2-{[(2R,5R)-2-Methyl-5-{3-[(1S)- 2,2,2-trifluor...)
Affinity DataIC50: 41.2nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404278(US10017504, 11)
Affinity DataIC50: 41.4nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404332(2-(3-{(3R,6R)-6-Methyl-1-[(2-pyrimidin-2- ylphenyl...)
Affinity DataIC50: 42.3nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404308((2-{5-[(3R,6R)-6-Ethyl-1-{[2-(2H-1,2,3-triazol-2-y...)
Affinity DataIC50: 42.4nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404338(2-{3-[(3R,6R)-1-{[2-(2,2- Difluoroethoxy)pyridin-3...)
Affinity DataIC50: 42.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404336(Methyl 2-({(2R,5R)-5-[5-(1-hydroxy-1- methylethyl)...)
Affinity DataIC50: 43.6nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404334(2-(3-{(3R,6R)-6-Methyl-1-[(4-pyrimidin-2- ylthioph...)
Affinity DataIC50: 46.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404256((1 2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-...)
Affinity DataIC50: 46.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404321((1-Cyclopropyl-1-{5-[(3R,6R)-6-methyl-1-{[2-(2H-1,...)
Affinity DataIC50: 47.3nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404289(2-(5-{(3R,6R)-6-Methyl-1-[(2- pyrimidin-2- ylpheny...)
Affinity DataIC50: 51.4nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404307(2-{5-[(3R,6R)-1-{[2-(2,2- Difluorocyclopropyl)phen...)
Affinity DataIC50: 52.4nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404329(2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-tetrazol- 2-yl)ph...)
Affinity DataIC50: 63.8nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404323(US10017504, 55 | 2-{5-[(3R,6R)-6-Methyl-1- {[2-(2H...)
Affinity DataIC50: 76.1nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404284(((2S)-1,1-Difluoro-2-{3-[(3R,6R)-6-methyl-1-{[2-(2...)
Affinity DataIC50: 92nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404257((1-(2-((2R,5R)-5-(5-(2-Hydroxypropan-2-yl)isoxazol...)
Affinity DataIC50: 104nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404319(((1R)-2,2,2-Trifluoro-1-(5-{(3R,6R)-6-methyl-1-[(2...)
Affinity DataIC50: 110nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404318((1R)-2,2,2-trifluoro-1-(5-{(3R,6R)-6-methyl-1-[(2-...)
Affinity DataIC50: 112nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404317(((1S)-2,2,2-Trifluoro-1-(5-{(3R,6R)-6-methyl-1-[(2...)
Affinity DataIC50: 113nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404299(2-{5-[(3R,6R)-6-Methyl-1-{[2- (2H-tetrazol-2- yl)p...)
Affinity DataIC50: 124nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404302(2-(5-{(3R,6R)-6-Methyl-1-[(2- phenylpyridin-3- yl)...)
Affinity DataIC50: 134nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404304(2-{5-[(3R,6R)-1-{[2-(2,2- Difluoroethoxy)phenyl]ca...)
Affinity DataIC50: 140nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404320(((1S)-2,2,2-Trifluoro-1-(5-{(3R,6R)-6-methyl-1-[(2...)
Affinity DataIC50: 146nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404311(((1R)-2,2,2-Trifluoro-1-{5-[(3R,6R)-6-methyl-1-{[2...)
Affinity DataIC50: 154nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404312(US10017504, 43)
Affinity DataIC50: 162nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404298(2-(5-{(3R,6R)-1-[(2- Ethoxyphenyl)carbonyl]-6- met...)
Affinity DataIC50: 178nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404305(2-{5-[(3R,6R)-6-Methyl-1-{[2- (2,2,2-trifluoroetho...)
Affinity DataIC50: 212nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 140 total ) | Next | Last >>
Jump to: